Tempus AI (TEM)
Interactive Stock Price & EPS Projection Dashboard
Select a scenario or adjust the sliders to model outcomes in real-time.
Model Assumptions
Live Projections
1-Year Target
$0.00
EPS: $0.00
3-Year Target
$0.00
EPS: $0.00
5-Year Target
$0.00
EPS: $0.00
Disclaimer: This is a financial model for illustrative purposes only, based on a simplified set of assumptions. It does not constitute investment advice. Financial markets are volatile and subject to numerous risks not captured in this model.
Tempus AI (TEM)
An Analysis of Growth Drivers & Future Valuation
The Two Engines of Growth
Tempus AI’s value is driven by two synergistic revenue streams: its established Genomics testing business and its rapidly expanding, high-margin Data & Services segment. While Genomics provides the foundation, the data collected fuels a powerful analytics platform, creating a flywheel effect for future growth.
Projected Revenue Growth & Composition (Base Case)
The Next Frontier: Minimal Residual Disease (MRD)
A significant catalyst for Tempus is its entry into the Minimal Residual Disease (MRD) testing market. This technology detects trace amounts of cancer after treatment, guiding further therapy. Capturing even a modest share of this multi-billion dollar market presents a substantial upside.
Projected MRD Market Capture (Year 5)
Total Addressable Market (TAM) by 2030
$4.5B
Base Case Revenue Opportunity (15% Share)
$675M
Valuation Scenarios & Projections
By modeling different outcomes for key growth drivers, we can project a range of potential valuations. The following Bear, Base, and Bull scenarios illustrate how sensitive the stock price is to growth rates, market capture, and valuation multiples.
Key Assumptions by Scenario
| Metric | Bear Case | Base Case | Bull Case |
|---|---|---|---|
| Genomics CAGR | 15% | 25% | 40% |
| Data & Services CAGR | 20% | 30% | 50% |
| Peak MRD Share (Yr 5) | 5% | 15% | 30% |
| EV/Sales Multiple | 6.0x | 10.0x | 15.0x |
| Net Income Margin (Yr 5) | 10% | 20% | 30% |
5-Year Projected Price & EPS Targets
Investment Summary
Tempus presents a compelling growth story at the forefront of personalized medicine. The valuation is highly dependent on execution, but the potential for significant shareholder return is clear under favorable conditions.
Dual Revenue Foundation
Strong core genomics business provides a stable base, while the data analytics segment offers high-margin, scalable growth.
Multiple Growth Levers
Future value is not dependent on a single factor, with organic growth, new market penetration (MRD), and margin expansion all contributing.
Key Factors to Watch
Investors should closely monitor the adoption rate of new tests, the growth trajectory of data services revenue, and progress in capturing MRD market share.